Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.

Leukemia - 1 Jun 2008

Zhang H, Trachootham D, Lu W, Carew J, Giles F J, Keating M J, Arlinghaus R B, Huang P

Abstract excerpt

Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehyde Dehydrogenase
Share to Anticarcinogenic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caspase 3

Share to Fusion Proteins, bcr-abl

Share to Glutathione

Share to Imatinib Mesylate

Share to Isothiocyanates

Share to Precursor Cells, B-Lymphoid

Source

Open in PubMed Open full text

Identifiers

PMID: 18385754
DOI: 10.1038/leu.2008.74
PMCID: PMC2585768

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.PMID 18385754Read ↗

Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.Semantic proximity Read ↗

Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.Semantic proximity Read ↗

Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.Semantic proximity Read ↗

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells.Semantic proximity Read ↗

Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib ResistanceSemantic proximity Read ↗

Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.Semantic proximity Read ↗

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.Semantic proximity Read ↗

Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs.Semantic proximity Read ↗

Reversal of Multidrug Resistance in Cancer by Multi-Functional FlavonoidsSemantic proximity Read ↗

NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.Semantic proximity Read ↗

Echinacoside induces apoptotic cancer cell death by inhibiting the nucleotide pool sanitizing enzyme MTH1Semantic proximity Read ↗

Gallic Acid Enhances the Efficacy of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration and Modulation of Oncogenic Signaling PathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.